New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
11:40 EDTZIOP, THLDThreshold higher after Ziopharm terminates STS drug development
Threshold Pharmaceuticals (THLD) shares are trading higher today after rival cancer drug discovery company Ziopharm (ZIOP) terminated its development of palifosfamide. WHAT'S NEW: Earlier today, Ziopharm announced that its Phase 3 trial of palifosfamide for the treatment of metastatic soft tissue sarcoma, or STS, in the first-line setting did not meet its primary endpoint of progression-free survival. Like Ziopharm, Threshold focuses on the discovery and development of cancer therapeutics and is also in the process of evaluating a drug to treat patients with soft tissue sarcoma with its development of TH-302. WHAT'S NOTABLE: Threshold's TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer. Both Phase 3 trials are being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TODAY'S PRICE ACTION: Shares of Threshold Pharmaceuticals are up 11c, or 2.3% to $4.90 in late morning trading. Meanwhile, shares of Ziopharm, which were downgraded by at least four analyst firms after its announcement, plunged 62% to $1.94.
News For THLD;ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 7, 2014
16:48 EDTTHLDThreshold Pharmaceuticals announces data from TH-302 study
Threshold Pharmaceuticals announced new preliminary data from the Phase 2 component of an ongoing company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib, Velcade, and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. The median number of prior therapies was 8. The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses were observed in 2 of 7 evaluable patients overall and 2 of 4 evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California.
14:10 EDTTHLDAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use